TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04510220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly subcutaneous injection that is in development for MS. Ofatumumab drug product (also referred as OMB157) is formulated as 20 mg/0.4 mL (50 mg/mL) solution for injection, provided in autoinjectors, for subcutaneous administration. The autoinjectors contain a small overfill to allow for a complete withdrawal of the labeled amount (20 mg) of ofatumumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
Study: NCT02310750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 oral solution/suspension
Description: Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given during the single ascending and multiple dose periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 tablet
Description: PF-06700841 tablet formulation administered during the bioavailability / food effect investigation
Study: NCT03671603

Intervention type: DRUG
Intervention: Iodixanol
Description: Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
Study: NCT03719456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde Intrarenal Surgery
Study: NCT03424681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil 300 mg by mouth daily
Study: NCT03970304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivotif Typhoid Oral Vaccine
Description: The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivotif Typhoid Oral Vaccine
Description: The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
Study: NCT00519857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tibolone
Description: 1.25 mg p.o, once daily for 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet p.o, once daily for 3 years
Study: NCT03424681

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04405700

Intervention type: OTHER
Intervention: Pharmacovigilance surveillance program
Description: The pharmacovigilance (PV) surveillance program will prospectively monitor for adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated with the International Epidemiology Databases to Evaluate consortium (IeDEA).

Intervention type: OTHER
Intervention: Pharmacovigilance surveillance program
Description: The pharmacovigilance (PV) surveillance program will prospectively monitor for adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated with the International Epidemiology Databases to Evaluate consortium (IeDEA).

Intervention type: OTHER
Intervention: Pharmacovigilance surveillance program
Description: The pharmacovigilance (PV) surveillance program will prospectively monitor for adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated with the International Epidemiology Databases to Evaluate consortium (IeDEA).
Study: NCT01600157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulant laparoscopic nephrectomy
Description: The patients with a renal cancer diagnosis with be schedule to enter the project if they meet the inclusion criteria of the project and the postoperative period will be recorded to identified the limiting factors for ambulant laparoscopic nephrectomy.
Study: NCT01873365

Intervention type: OTHER
Intervention: Data collection
Description: Case report forms (CRFs), logbooks and booklets.
Study: NCT00991354

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-B
Description: DNA vaccine encoding the Gag, Pol, and Env proteins of HIV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-B
Description: DNA vaccine encoding the Gag, Pol, and Env proteins of HIV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-B
Description: DNA vaccine encoding the Gag, Pol, and Env proteins of HIV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 DNA plasmids
Description: Adjuvant for HIV vaccines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 DNA plasmids
Description: Adjuvant for HIV vaccines
Study: NCT04458948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400 mg BID, on day 1 and then 200 mg BID day 2 through 7 IV or po for 5 days. If the condition of the patient does not allow for oral therapy, HCQ can be given via a feeding or NG tube. Azithromycin can be given intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 500 mg, IV or po for 5 days
Study: NCT04616157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT-I
Description: Cognitive-behavioral therapy for insomnia
Study: NCT01934218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gel-One

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PBS
Study: NCT05520580

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mother's push during CS
Description: after uterotomy, the mother was instructed and motivated to push for the delivery of the head and the shoulders of the baby. Simultaneously, the surgical assistant applied fundal pressure to support the mothers pushing if necessary
Study: NCT00288158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT04214132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Counselling Application using Artificial Intelligence
Description: Intervention comprises of four Virtual Patients scenarios that aimed to improve nursing undergraduates communication skills in a clinical setting. These scenarios are based on authentic clinical cases (adapted from the real-life clinical case studies) focusing mainly on the communication aspects. Scenarios included 1) a middle-aged pregnant woman in her third trimester experiencing pain, 2) a middle-aged lorry driver who self-admitted to the hospital due to relapse of depressive symptoms, 3) changing a bloody dressing of a middle-aged male patient who had an operation 3 days ago, and 4) communicating with a fellow stressed student during their final preregistration clinical posting period.
Study: NCT01333124

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy with Gemcitabine
Description: All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: chemoradiotherapy with Gemcitabine
Description: Radiation: chemoradiotherapy with Gemcitabine
Study: NCT03649828

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic milk fermented with kefir grains
Description: Participants received probiotic milk fermented with kefir grains for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curd
Description: Participants received the curd for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
Study: NCT01573845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating + Eco-Friendly Campaign
Description: Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Eating Campaign
Description: Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements
Study: NCT03910257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education module
Description: 12 activities of nutrition education module will deliver by the teacher. The activities consists of coloring my meal plate, playing pictures, story telling: Zizi and Ziko, pictures station, fruits and vegetables card, cooking class, planting bean sprouts, field visit to fruits and vegetables garden, making collages, dot to dot, watching video, making healthy snacks
Study: NCT03369600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supersonic Imagine Aixplorer SWE Ultrasound Imaging
Description: Consented women will attend 2+ sessions where they will be imaged using the Supersonic Imagine Aixplorer for Shear Wave Elastography imaging.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supersonic Imagine Aixplorer SWE Ultrasound Imaging
Description: Consented women will attend 2+ sessions where they will be imaged using the Supersonic Imagine Aixplorer for Shear Wave Elastography imaging.
Study: NCT01002157

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (Vitamin K2)
Description: Menaquinone-7 (Vitamin K2)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Capsules containing no Menaquinone-7
Study: NCT03263520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone Decanoate
Description: Drug administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Drug administration
Study: NCT03558997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab was administered SC in a single-use, pre-filled glass syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab was administered SC in a single-use, pre-filled glass syringe
Study: NCT03369600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supersonic Imagine Aixplorer SWE Ultrasound Imaging
Description: Consented women will attend 2+ sessions where they will be imaged using the Supersonic Imagine Aixplorer for Shear Wave Elastography imaging.
Study: NCT02040480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 Gelatin Capsule
Description: White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 Gelatin Capsule
Description: White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 Gelatin Capsule
Description: White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 Gelatin Capsule
Description: White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 Gelatin Capsule
Description: White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 Gelatin Capsule
Description: White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 IR Tablet
Description: White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 IR Tablet
Description: White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 IR Tablet
Description: White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 IR Tablet
Description: White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 IR Tablet
Description: White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 IR Tablet
Description: White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
Study: NCT03498248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenograstim
Description: injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy
Study: NCT03558997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timothy Grass SCIT
Description: Timothy grass extract was administered SC.
Study: NCT02837341

Intervention type: DEVICE
Group type: OTHER
Intervention: Philips®Vital Sign Device - Camera-based system (Prototype)
Description: Respiratory rates monitored via camera-based system and capnography simultaneously The Philips Vital Sign Device will record chest movements by camera. The program will use an algorithm to convert the chest movements into the respiratory rate
Study: NCT03349450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Description: Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
Study: NCT01289912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast.
Study: NCT03786679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasling ER III orthosis
Description: Application of orthosis and start of rehabilitation after four weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasling ER III orthosis
Description: Application of orthosis and start of rehabilitation after four weeks.
Study: NCT02940990

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT concurrent with GM-CSF
Description: SBRT and GM-CSF 125ug/m2 for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel
Description: two-drug regimen
Study: NCT03558997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timothy Grass SCIT
Description: Timothy grass extract was administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching dupilumab
Description: Placebo matching dupilumab was prepared in the same formulation without the addition of protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching dupilumab
Description: Placebo matching dupilumab was prepared in the same formulation without the addition of protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SCIT
Description: Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SCIT
Description: Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract
Study: NCT03282435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK cells with PD-1 blocking
Description: CIK cellular therapy with PD-1 blocking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard lung cancer treament
Description: standard non-small cell lung cancer treatment: surgery, chemotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard lung cancer treament
Description: standard non-small cell lung cancer treatment: surgery, chemotherapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CIK cells without PD-1 blocking
Description: CIK cellular therapy without PD-1 blocking
Study: NCT03548376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: Hippotherapy is a therapeutic intervention that is typically conducted by a physical or occupational therapist and is aimed at improving impaired body function. Hippotherapy has been proposed as a technique to decrease the energy requirements and improve walking in patients with cerebral palsy. It is thought that the natural swaying motion of the horse induces a pelvic movement in the rider that simulates human ambulation. In addition, variations in the horse's movements can also prompt natural equilibrium movements in the rider.
Study: NCT01306253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1
Study: NCT00306631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC-1
Description: Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle
Study: NCT02940990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel
Description: two-drug regimen
Study: NCT03152552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 was supplied in different doses as tablets taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 was supplied in different doses as tablets taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 was supplied in different doses as tablets taken orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as tablets and capsules taken orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin was supplied as capsules taken orally.
Study: NCT03421691

Intervention type: DEVICE
Group type: OTHER
Intervention: excel V Laser
Description: excel V Laser Genesis procedure utilizing 1064 nm laser